GlassScriptPhysician profile
Mike Kozminski
NPI 1093816316
$6,731.95
in general payments reported to CMS, 2019-2025
35 companies · $68.74 in 2025
The $68.74 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,589 · 2020: $612 · 2021: $960 · 2022: $392 · 2023: $91.04 · 2024: $18.64 · 2025: $68.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,663.85 | 2019-2020 | |
| Abbvie INC. | $386.69 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $381.06 | 2019-2022 | |
| Astellas Pharma US INC | $293.27 | 2019-2023 | Xtandi |
| Janssen Biotech, INC. | $266.37 | 2019-2022 | |
| Amgen INC. | $192.84 | 2019-2022 | |
| Pfizer INC. | $186.30 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $166.59 | 2019-2021 | |
| Olympus America INC. | $114.41 | 2019-2022 | |
| Allergan, INC. | $107.59 | 2019-2021 | |
| Blue Earth Diagnostics | $94.00 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $89.34 | 2023-2025 | Orgovyx |
| Medtronic, INC. | $81.52 | 2021 | |
| Convatec INC. | $70.80 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $65.28 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $62.93 | 2021-2022 | |
| Neotract INC. | $58.63 | 2019 | |
| Myriad Genetic Laboratories, INC. | $48.12 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.44 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $41.87 | 2022 | |
| Boston Scientific Corporation | $40.08 | 2020-2021 | |
| Coloplast Corp | $37.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $36.19 | 2022 | |
| Procept Biorobotics Corporation | $30.59 | 2022 | |
| Medtronic USA, INC. | $22.82 | 2019 | |
| Telix Pharmaceuticals | $21.29 | 2023 | Illuccix |
| Therapeuticsmd, INC. | $20.38 | 2019 | |
| 180 Medical, INC. | $16.82 | 2020 | |
| Teleflex LLC | $14.86 | 2021 | |
| Axonics, INC. | $14.83 | 2021 | |
| Accord Healthcare, INC. | $14.66 | 2022 | |
| Baudax Bio INC. | $13.91 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $12.36 | 2019 | |
| Antares Pharma, INC. | $11.34 | 2021 | |
| Zyla Life Sciences, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mike Kozminski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.